Carrie Bourdow
Chief Executive Officer presso TREVENA, INC.
Patrimonio netto: 43 442 $ in data 31/03/2024
Profilo
Carrie L.
Bourdow is currently the Chairman, President & Chief Executive Officer at Trevena, Inc. She previously served as an Independent Director at Sesen Bio, Inc. from 2020 to 2023 and at Nabriva Therapeutics Plc from 2017 to 2023.
Prior to that, she was the Vice President-Marketing at Cubist Pharmaceuticals LLC from 2013 to 2015.
Ms. Bourdow holds an undergraduate degree from Hendrix College and an MBA from Southern Illinois University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
TREVENA, INC.
0.51% | 09/02/2024 | 93 214 ( 0.51% ) | 42 878 $ | 31/03/2024 |
NABRIVA THERAPEUTICS PLC
0.01% | 31/01/2023 | 397 ( 0.01% ) | 564 $ | 31/07/2023 |
Posizioni attive di Carrie Bourdow
| Società | Posizione | Inizio |
|---|---|---|
| TREVENA, INC. | Chief Executive Officer | 01/10/2018 |
Precedenti posizioni note di Carrie Bourdow
| Società | Posizione | Fine |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 30/07/2023 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 07/03/2023 |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/05/2015 |
Formazione di Carrie Bourdow
| Hendrix College | Undergraduate Degree |
| Southern Illinois University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| TREVENA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Aziende private | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Carrie Bourdow
